INS and diabetes mellitus: In a mouse model of slowly progressive diabetes that does not show hyperglycemia until four weeks following low doses STZ administration [71], SDC4-KO mice showed hyperglycemia from four days after STZ administration and reduced casual insulin secretion and pancreatic β-cell mass [70].